Agoracom Blog Home

Posts Tagged ‘CSE’

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:49 AM on Saturday, May 8th, 2021

A weekly summary of Novamind news and media

FEATURES May 7, 2021

Novamind Expands Footprint of Psychedelic Clinics

Our CEO Yaron Conforti and CMO Reid Robison discuss the news of our clinic expansion and how this further develops our model for scaling across the U.S.

FEATURES May 5, 2021

Pierre Bou-Mansour Discusses the Initial Phase of Novamind’s National Expansion Strategy

Our Chief Operating Officer speaks with the Wall Street Reporter about our clinic expansion, the key drivers of our growth, and the importance of set and setting in our clinics.

View all media

Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics

May 4, 2021

View all press releases

A Psychedelic Drug Passes Big Test for PTSD Treatment

In a soon-to-be-published study, MDMA and therapy are showing promising results in the treatment of PTSD, with over 67 percent of participants no longer qualifying for a diagnosis two months after treatment.

Why Psychedelics, Big in the 1960s, Are Drawing New Interest Now

Long misunderstood, psychedelics are back in the spotlight as more and more research is being done on the efficacy and positive mental health benefits they hold.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

VIDEO – Empower Clinics $CBDT.ca $EPWCF Shareholder Q&A With CEO Steve McAuley – Part 1 $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:23 PM on Friday, May 7th, 2021

PART 1 of Empower Clinics Shareholder Q&A with CEO Steve McAuley.

Topics Covered:

  • Annual Financials
  • KAI Labs
  • Clinics / Rexall
  • KAI Saliva
  • Pipelines

Part 2 next week.

AGORACOM Small Cap 60: Valeo $VPH $VPHIF Blood Clot Prevention Drug Approved By Ont Drug Plan, Other Provinces To Follow Suit $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 10:43 AM on Friday, May 7th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

VIDEO – $HPQ.ca Silicon Going After $2.2 Billion Fumed Silica Market Is A “Natural Extension, Potentially Lucrative Offshoot” $ENPH $BE $NNO $PYR

Posted by AGORACOM-JC at 4:07 PM on Tuesday, May 4th, 2021

HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.

If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:

Today, the Company announced  HPQ Silicon and Pyrogenesis Evaluating a Low-cost and Environmentally Friendly Plasma Based Process to Manufacture Fumed Silica

To discuss the importance and the implications of this milestone, this excerpt from the press release says it all:

Combining HPQ Silicon High Purity Quartz initiatives with PyroGenesis industry leading knowhow in the development of commercial plasma processes, this new process could revolutionize the manufacturing of Fumed Silica, give HPQ and PyroGenesis a market leadership in its green manufacturing and pivot production back to North America, all the while allowing end users to improve their environmental footprint.

 Watch this great interview with $HPQ CEO Bernard Tourillon to understand why Fumed Silica is a winnable market and how far advanced they are with PyroGenesis on this initiative.

VIDEO – Liquid Avatar $LQID Digital ID and Monetization Gets Huge Boost From “Building A Digital Ontario” News $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 4:03 PM on Tuesday, May 4th, 2021

When the Facebook data privacy scandal broke out, the world woke up to just how badly our individual data was being traded, used and most importantly, the amount of profit being generated by major corporations at our expense.

This led to the enactment of the biggest data privacy laws in history.  Specifically, General Data Protection Regulation (GDPR) out of Europe and the California Consumer Privacy Act (CCPA).

Enter $LQID. The Company Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.

More than just lip service, $LQID has made some major announcements, including joining the Trust Over IP Foundation, which includes over 170 members including IBM, Mastercard, Accenture and many other global leaders who are defining a complete architecture for Internet-scale digital trust.

Does that sound like a mouthful?  Yeah, it does.  But all you have to really understand for now is that digital ID, privacy and monetization is going to become a reality in the very near future.  Government regulations are enforcing it.  Consumers are demanding it and $LQID is delivering it at such an advanced scale that the Trust Over IP Foundation provided them with a strategic role as a Steering Member.

If that wasn’t enough proof for you, Google  validated the $LQID business model with this stunning announcement at the beginning of March:

 Google announces major shift away from precision-targeting of ads based on everything you do on the internet

  • Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
  • Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
  • “Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,

 What is the potential outcome of this major shift by Google?

  “Google’s decision could upend the ad industry, which has relied on these types of tracking tools”  

Now the data privacy and monetization game is underway with LQID sitting in a great position within the industry and the dominant position within the small cap world.  That dominant position got even stronger today when $LQID announced Liquid Avatar Congratulates the Ontario Government on the Release of its Digital Strategy  

WHY IS THIS SO IMPORTANT?

If consumers are going to switch to Liquid Avatar to protect and monetize their identity, the switch to Digital ID by Canada’s biggest Province is simply a monster catalyst:  The Ontario government strategy outlines ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments such as: 

  • the creation of a new data authority; 
  • a new digital artificial intelligence (AI) framework to guide responsible use of AI; and 
  • the introduction of a new government-issued digital ID that lets people prove who they are online.

If you didn’t know any better, you would think CEO David Lucatch wrote the Ontario Digital Strategy paper himself!  He didn’t but the next best thing is this interview with CEO David Lucatch for an even deeper discussion into what this all means for $LQID and YOU.

Novamind $NM.ca $NVMDF Doubles in Size, Adds Four New Psychedelic Mental Health Clinics $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:38 AM on Tuesday, May 4th, 2021
  • Announced that it will open four new Cedar Psychiatry clinics doubling its network to eight total locations
  • Begun construction on three of the New Clinics and leased a fourth additional property
  • Expanded capacity from the New Clinics is forecasted to increase Novamind’s patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021

New clinics represent the first phase of Novamind’s national expansion strategy

TORONTO, ON / May 4, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics (the “New Clinics”), doubling its network to eight total locations.

The expanded capacity from the New Clinics is forecasted to increase Novamind’s patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021, a 225% increase.

Novamind has begun construction on three of the New Clinics and leased a fourth additional property. Scheduled to open between July and September 2021, the New Clinics represent the initial phase of Novamind’s national expansion strategy whereby the Company is replicating the successful operating track record of its current clinics in Utah, at scale, ahead of its expansion into other American states in 2021.

Novamind’s investment in the expansion of its clinic network follows a significant increase in demand from clients for mental health services to address existing unmet needs and the effects of the Covid-19 pandemic. All Cedar Psychiatry clinics currently have a 2-week wait time for booking new appointments.

The New Clinics will each offer a range of treatments including ketamine-assisted psychotherapy, SpravatoTM, Cognitive Behavioral Therapy (CBT) and Transcranial Magnetic Stimulation (TMS). The Draper, Murray, and Salt Lake City locations will also offer opportunities for patients to participate in clinical trials for psychedelic medicine that are led by Cedar Clinical Research, Novamind’s clinical research arm. The Park City location will uniquely serve as both a clinic and a retreat center offering therapeutic psychedelic experiences, leveraging its community’s reputation as a world-class destination.

“We are doubling the size of our clinic network six months ahead of schedule, with the added capacity enabling us to scale to 65,000 client visits in 2021,” said Yaron Conforti, CEO and Director of Novamind. “Expect continued and aggressive growth as we expand Novamind’s clinic network and clinical research infrastructure ahead of the FDA’s anticipated approvals of MDMA and psilocybin.”

Novamind is making additional strategic investments in the infrastructure required to support the rapid growth in client volumes at its clinics. A new, dedicated call center is under construction and will enhance Novamind’s network of eight clinics by improving communications with clients and referring physicians, as well as facilitating the significant increase in processing of insurance reimbursements. Additional details for each of the New Clinics and the call center will be announced in subsequent press releases.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

VIDEO – Sheldon Inwentash $IDK $IDKFF Praises Loop Insights’ $MTRX $RACMF “Monumental Alliance” With Industry Powerhouse NielsenIQ $AT.ca $QTRH.ca $SNSR $BSQR $PTS.ca

Posted by AGORACOM-JC at 9:03 AM on Monday, May 3rd, 2021
IDK-square-for-blog

VIDEO – Datametrex $DM.ca $DTMXF CEO Talks Record-Breaking FY2020 with $12.3M In Revenue, Covid-19 Test Kits and More $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:12 PM on Friday, April 30th, 2021

When it comes to small-cap companies, tech-focused Datametrex AI is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.

Financial Highlights for year ending December 31, 2020:

  • Revenue of $12.3M vs. $3.4M for FY 2019
  • An increase of 264%

We sat down with CEO Marshall Gunter to discuss these highlights, the COVID-19 landscape, telemedicine, 2021 plans, and more.

Check out the interview down below.

VIDEO – Valeo Pharma $VPH $VPHIF Drug Projected To Add $30M / Year Revenue Gets Ontario Public Drug Coverage $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:22 PM on Thursday, April 29th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • 2020 net revenues of $7.5 million
  • 2021 is expected to double to $15 million
  • Commercializing Novartis Asthma Therapies In Canada
  • Closed $6.6 Million Financing With Insiders Taking ~ 40% 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-20% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $40,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-20% market share without one hell of a fight.  Saviuk agreed and gave the following 3 reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

More than just lip service, $VPH just announced that Redesca is now listed on the Ontario Public Drug Program, which means the government will cover its costs for all public use.  Moreover, $VPH expects additional Provinces to follow.   

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

VIDEO – PlantX $VEGA.ca $PLTXF Nets Venus Williams as Ambassador, Launches 2K Products On Hudson’s Bay Marketplace $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 4:20 PM on Wednesday, April 28th, 2021

The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.

PlantX Life (VEGA:CSE) (PLTXF:OTCQB) Is The One Stop Shop For Everything Plant Based + The  Digital Face of The Plant -Based Community   More than just lip service, $VEGA reported RECORD revenues of  $1,565,982 for March 2021 and $1,353,613 for February 2021.

The company announced Tennis Champion and Entrepreneur Venus Williams as Company Ambassador and if that’s not enough, they also launched Over 2000 Products on Hudson’s Bay Marketplace.

With a line up of plant based products and services that includes:

  • Plant Based Meal Delivery
  • Plant Based Snack Products
  • Plant Based Pet foods
  • Plant Based Restaurant Locator
  • Plant Based Recipes
  • Plant Based Essentials …. Like Chocolate (Essential?  You Bet)
  • And …… Plant Based …. PLANTS (It’s A BIG Business!)

If you believe in the massive paradigm shift towards plant based foods and more, be sure to watch and share this great interview with PlantX CEO Julia Frank.